Back to results
US 2019/0290694 A1Published application
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
OwnerAnne-Sophie GAUTRON, Philippe DUCHATEAU +2inventors
InventorsAnne-Sophie GAUTRON, Philippe DUCHATEAU, Laurent POIROT, Julien VALTON
Life of this patent
Estimating the term…
Abstract
The present invention relates to gene editing methods to engineer primary immune cells that are made resistant to proteasome inhibitors, such as Bortezomib, Carfilzomib, Ixazomib, Marizomib, Delanzomib or Oporozomib, for their use in cell immunotherapy in combination with proteasome inhibitor treatments.
Claims24
1-47. (canceled)
A method for engineering proteasome inhibitor resistant cells, wherein said method comprises the steps of:
- providing primary immune cells;
- performing gene editing of an endogenous gene in said primary immune cells with a sequence-specific endonuclease reagent selected from an RNA-guided endonuclease, a TALE-nuclease, and a Zinc-Finger-nuclease;
- selecting cells that have acquired resistance to at least a LD50 dose of a proteasome inhibitor selected from bortezomib, carfilzomib, ixazomib, marizomib, delanzomib or oporozomib, and
- expanding the selected cells.
1 more element
Dependencies are inferred from the claim text.